Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-synuclein radiotracer
- Development stage
- Unknown
- Lead developer
- AC Immune
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
An alpha-synuclein radiotracer is a radiolabeled imaging agent designed to selectively bind to pathological aggregates of alpha-synuclein (α-syn) in the brain. These tracers are utilized in positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging to non-invasively visualize and monitor the progression of synucleinopathies, such as Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Developing these tracers has been historically challenging due to the low abundance of α-syn aggregates compared to amyloid-beta or tau, and the requirement for high selectivity over other misfolded proteins. Several candidates, including [18F]ACI-12589 (developed by AC Immune), [11C]MODAG-005, and [18F]MODAG-009 (developed by MODAG), are currently undergoing clinical evaluation.
- Other names
- alpha-synuclein PET radiotraceralpha-synuclein PET traceralpha-synuclein imaging agentalpha-synuclein imaging traceralpha-synuclein tracer
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))Amyloid-beta aggregate (N-terminal epitope)Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on alpha-synuclein radiotracer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-synuclein radiotracer.